Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

Dillman R. Antibodies as cytotoxic therapy. J Clin Oncol 119; 12: 1497–515.

Meeker, 1985, A clinical trial of anti-idiotype therapy for B cell malignancy, Blood, 65, 1349, 10.1182/blood.V65.6.1349.bloodjournal6561349

Brown, 1989, Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon, Blood, 73, 651, 10.1182/blood.V73.3.651.651

Maloney, 1992, Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells, Blood, 80, 1502, 10.1182/blood.V80.6.1502.1502

Tang, 1996, Immunosuppressive toxicity of CAMPATH 1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma, Leuk Lymph, 24, 930191, 10.3109/10428199609045717

Scheuemann, 1995, CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy, Leuk Lymph, 18, 385, 10.3109/10428199509059636

Press, 1987, Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas, Blood, 69, 584, 10.1182/blood.V69.2.584.584

Press, 1993, Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support, N Engl J Med, 329, 1219, 10.1056/NEJM199310213291702

Kaminski, 1993, Radioimmunotherapy of B-cell lymphoma with [131I] anti-Bl (anti-CD20) antibody, N Engl J Med, 329, 459, 10.1056/NEJM199308123290703

Grillo-López, 1995, Phase I study of IDEC-Y2B8: 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin’s lymphoma, Blood, 86, 55a

Grillo-López, 1996, Treatment of relapsed non-Hodgkin’s lymphoma (NHL) using the 90-Yttrium (90-Y) labeled anti-CD20 monoclonal antibody (Mab) IDEC-Y2B8: A phase I clinical trial, Ann Oncol, 7, 57

Witzig, 1997

Wiseman, 1997

Reff, 1994, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20, Blood, 83, 435, 10.1182/blood.V83.2.435.435

Liu, 1987, Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity, J Immunol, 139, 3521, 10.4049/jimmunol.139.10.3521

LoBuglio, 1989, Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response, Proc Natl Acad Sci USA, 86, 4220, 10.1073/pnas.86.11.4220

Mueller, 1990, Enhancement of antibody dependent cytotoxicity with a chimeric anti-GD2 antibody, J Immunol, 144, 1382, 10.4049/jimmunol.144.4.1382

Maloney, 1994, Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma, Blood, 84, 2457, 10.1182/blood.V84.8.2457.2457

McLaughlin, 1996, IDEC-C2B8 anti-CD20 antibody: Final report on a phase III pivotal trial in patients with relapsed low-grade or follicular lymphoma, Blood, 90a, 88

Maloney, 1997, IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma, Blood, 90, 2188, 10.1182/blood.V90.6.2188

Grillo-López, 1997, Development of response criteria for low-grade or follicular lymphomas and application in a 166 patient study, Exp Hematol, 25, 732

Osterborg, 1997, Phase II multicentre study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia, J Clin Oncol, 15, 1567, 10.1200/JCO.1997.15.4.1567

Hekman, 1991, Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody, Cancer Immunol Immunother, 32, 364, 10.1007/BF01741331

Remlinger, 1984, Murine monoclonal anti-T-cell antibodies for the treatment of steroid resistant acute graft-versus-host disease, Hum Immunol, 9, 21, 10.1016/0198-8859(84)90004-1

Hu, 1989, A phase la clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies, Hematological Oncol, 7, 155, 10.1002/hon.2900070207

Hale, 1988, Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H, Lancet, 2, 1394, 10.1016/S0140-6736(88)90588-0

Knox, 1996, Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody, Blood, 87, 893, 10.1182/blood.V87.3.893.bloodjournal873893